HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

MYTHS ABOUT TRANSDERMAL DRUG DELIVERY SYSTEM. Vikramjit Singh, Monika, Nawazish Alam

MYTHS ABOUT TRANSDERMAL DRUG DELIVERY SYSTEM.

Vikramjit Singh, Monika, Nawazish Alam.

International Journal of Natural Product Science 2012: Spl Issue 1: 5.

Abstract (RBIP-05)

When you hear the words transdermal drug delivery, what comes to mind? More than likely, you think about a simple patch that you stick onto your skin like an adhesive bandage, such as the nicotine patch. And for good reason, because adhesive transdermal patches, which utilize passive diffusion of drugs across the skin as the delivery mechanism, have been available on the US market for more than 20 years to treat systemic illnesses, and the predominant transdermal drug delivery (TDD) technology that has been approved by the FDA. In addition, because transdermal patches are user-friendly, convenient, painless, and offer multi-day dosing, it is generally accepted that they offer improved patient compliance. Clearly, the clinical benefits, industry interest, strong market, and regulatory precedence show why transdermal drug delivery has become a successful and viable dosage form. In this article a review of transdermal drug delivery technologies, while dispelling four myths about the function and capabilities of TDD systems and the TDD market.1: The transdermal drug delivery market is stagnant, 2: Transdermal drug delivery is an old technology, 3: All drugs that can be delivered transdermally are already on the market, 4: Transdermal drug delivery systems are not suitable for delivery of biotechnology drugs, such as protein/peptide pharmaceuticals.

Keyword: 4 Myths of TDDS, TDDS, Market of TDDS, Techniques of TDDS.
Attachments:
Time to create page: 0.12 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com